Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.6, and our video podcast, CANCER BUZZ TV.


During the past few years, scientific journals have published an increasing number of groundbreaking articles about the efficacy of employing T-cell bispecific antibodies (TRBAs) in cancer immunotherapy. The research is encouraging: More than 50 bispecific antibodies are currently in clinical trials. Below are links to recent scholarship and resources that can help practices better serve their patients who may be eligible for TRBA therapy, including education materials and information about financial resources. 

The Leukemia & Lymphoma Society (LLS) Materials

Fact Sheet


Financial Assistance for Patients

Information Specialists

LLS Information Specialists have expertise with bispecific products and can direct you to their programs and services on bispecific antibodies. For more information, visit www.lls.org/support/information-specialists.



Our Partner

LLS Logo

Our Supporter

This project is sponsored by Amgen.